Diverse Effects of Methylseleninic Acid on the Transcriptional Program of Human Prostate Cancer Cells

Molecular Biology of the Cell

Volumn 15, Issue 2, 2004, Pages 506-519

  Zhao, Hongjuan ^a   Whitfield, Michael L ^a   Xu, Tong ^a   Botstein, David ^a   Brooks, James D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CARBOXYFLUORESCEIN; COMPLEMENTARY DNA; METHYLSELENINIC ACID; PROSTATE SPECIFIC ANTIGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; SELENIUM; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER PREVENTION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; DNA MICROARRAY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENETIC REGULATION; GENETIC TRANSCRIPTION; HORMONE RESPONSE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOLECULAR CLONING; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ADENOCARCINOMA; CELL CYCLE; CELL DIVISION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NADPH DEHYDROGENASE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGANOSELENIUM COMPOUNDS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TUMOR CELLS, CULTURED;

EID: 0742288062     PISSN: 10591524     EISSN: None     Source Type: Journal    
DOI: 10.1091/mbc.E03-07-0501     Document Type: Article

References (60)

1. Andreadou, I., Menge, W.M., Commandeur, J.N., Worthington, E.A., and Vermeulen, N.P. (1996). Synthesis of novel Se-substituted selenocysteine derivatives as potential kidney selective prodrugs of biologically active selenol compounds: evaluation of kinetics of beta-elimination reactions in rat renal cytosol. J. Med. Chem. 39, 2040-2046.
2. Bhamre, S., Whitin, J.C., and Cohen, H.J. (2003). Selenomethionine does not affect PSA secretion independent of its effect on LNCaP cell growth. Prostate 54, 315-321.
3. Blader, I.J., Manger, I.D., and Boothroyd, J.C. (2001). Microarray analysis reveals previously unknown changes in Toxoplasma gondii-infected human cells. J. Biol. Chem. 276, 24223-24231.
4. Brooks, J.D., Goldberg, M.F., Nelson, L.A., Wu, D., and Nelson, W.G. (2002). Identification of potential prostate cancer preventive agents through induction of quinone reductase in vitro. Cancer Epidemiol. Biomarkers Prev. 11, 868-875.
5. Brooks, J.D., Metter, E.J., Chan, D.W., Sokoll, L.J., Landis, P., Nelson, W.G., Muller, D., Andres, R., and Carter, H.B. (2001a). Plasma selenium level before diagnosis and the risk of prostate cancer development. J. Urol. 166, 2034-2038.
6. Brooks, J.D., Paton, V.G., and Vidanes, G. (2001b). Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. Cancer Epidemiol. Biomarkers Prev. 10, 949-954.
7. Clark, L.C., et al. (1996). Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. J. Am. Med. Assoc. 276, 1957-1963.
8. Clark, L.C., et al. (1998). Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br. J. Urol. 81, 730-734.
9. Combs, G.F., Jr. (2001). Considering the mechanisms of cancer prevention by selenium. Adv. Exp. Med. Biol. 492, 107-117.
10. Davis, C.D., Zeng, H., and Finley, J.W. (2002). Selenium-enriched broccoli decreases intestinal tumorigenesis in multiple intestinal neoplasia mice. J. Nutr. 132, 307-309.
11. DePrimo, S.E., Diehn, M., Nelson, J.B., Reiter, R.E., Matese, J., Fero, M., Tibshirani, R., Brown, P.O., and Brooks, J.D. (2002). Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol. 3, RESEARCH0032.
12. DePrimo, S.E., Shinghal, R., Vidanes, G., and Brooks, J.D. (2001). Prevention of prostate cancer. Hematol. Oncol. Clin. North Am. 15, 445-457.
13. Dong, Y., Ganther, H.E., Stewart, C., and Ip, C. (2002). Identification of molecular targets associated with selenium-induced growth inhibition in human breast cells using cDNA microarrays. Cancer Res. 62, 708-714.
14. Dong, Y., Zhang, H., Hawthorn, L., Ganther, H.E., and Ip, C. (2003). Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res. 63, 52-59.
15. Duffield-Lillico, A.J., Reid, M.E., Turnbull, B.W., Combs, G.F., Jr., Slate, E.H., Fischbach, L.A., Marshall, J.R., and Clark, L.C. (2002). Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol. Biomarkers Prev. 11, 630-639.
16. Eisen, M.B., Spellman, P.T., Brown, P.O., and Botstein, D. (1998). Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95, 14863-14868.
17. el-Bayoumy, K. (1994). Evaluation of chemopreventive agents against breast cancer and proposed strategies for future clinical intervention trials. Carcinogenesis 15, 2395-2420.
18. El-Bayoumy, K. (2001). The protective role of selenium on genetic damage and on cancer. Mutat. Res. 475, 123-139.
19. El-Bayoumy, K., Richie, J.P., Jr., Boyiri, T., Komninou, D., Prokopczyk, B., Trushin, N., Kleinman, W., Cox, J., Pittman, B., and Colosimo, S. (2002). Influence of selenium-enriched yeast supplementation on biomarkers of oxidative damage and hormone status in healthy adult males: a clinical pilot study. Cancer Epidemiol. Biomarkers Prev. 11, 1459-1465.
20. Fleming, J., Ghose, A., and Harrison, P.R. (2001). Molecular mechanisms of cancer prevention by selenium compounds. Nutr. Cancer 40, 42-49.
21. Ganther, H.E. (2001). Selenium metabolism and mechanisms of cancer prevention. Adv. Exp. Med. Biol. 492, 119-130.
22. Ganther, H.E., and Lawrence, J.R. (1997). Chemical transformations of selenium in living organisms. Improved forms of selenium for cancer prevention. Tetrahedron 53, 12299-112310.
23. Gitig, D.M., and Koff, A. (2000). Cdk pathway: cyclin-dependent kinases and cyclin-dependent kinase inhibitors. Methods Mol. Biol. 142, 109-123.
24. Groszer, M., Erickson, R., Scripture-Adams, D.D., Lesche, R., Trumpp, A., Zack, J.A., Kornblum, H.I., Liu, X., and Wu, H. (2001). Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 294, 2116-2118.
25. Helzlsouer, K.J., Huang, H.Y., Alberg, A.J., Hoffman, S., Burke, A., Norkus, E.P., Morris, J.S., and Comstock, G.W. (2000). Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J. Natl. Cancer Inst. 92, 2018-2023.
26. Hoque, A., et al. (2001). Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes Control 12, 627-633.
27. Ip, C. (1998). Lessons from basic research in selenium and cancer prevention. J. Nutr. 128, 1845-1854.
28. Ip, C., Hayes, C., Budnick, R.M., and Ganther, H.E. (1991). Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res. 51, 595-600.
29. Ip, C., Thompson, H.J., and Ganther, H.E. (2000a). Selenium modulation of cell proliferation and cell cycle biomarkers in normal and premalignant cells of the rat mammary gland. Cancer Epidemiol. Biomarkers Prev. 9, 49-54.
30. Ip, C., Thompson, H.J., Zhu, Z., and Ganther, H.E. (2000b). In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res. 60, 2882-2886.
31. Ip, C., and White, G. (1987). Mammary cancer chemoprevention by inorganic and organic selenium: single agent treatment or in combination with vitamin E and their effects on in vitro immune functions. Carcinogenesis 8, 1763-1766.
32. Jiang, C., Wang, Z., Ganther, H., and Lu, J. (2001). Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res. 61, 3062-3070.
33. Jones, J.O., and Arvin, A.M. (2003). Microarray analysis of host cell gene transcription in response to Varicella-Zoster virus infection of human t cells and fibroblasts in vitro and scidhu skin xenografts in vivo. J. Virol. 77, 1268-1280.
34. Kim, Y.S., and Milner, J. (2001). Molecular targets for selenium in cancer prevention. Nutr. Cancer 40, 50-54.
35. Klein, E.A., Thompson, I.M., Lippman, S.M., Goodman, P.J., Albanes, D., Taylor, P.R., and Coltman, C. (2001). SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. J. Urol. 166, 1311-1315.
36. Lu, J. (2001). Apoptosis and angiogenesis in cancer prevention by selenium. Adv. Exp. Med. Biol. 492, 131-145.
37. Lu, J., and Jiang, C. (2001). Antiangiogenic activity of selenium in cancer chemoprevention: metabolite-specific effects. Nutr. Cancer 40, 64-73.
38. Lyons, A.B. (2000). Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J. Immunol. Methods 243, 147-154.
39. Medina, D., Thompson, H., Ganther, H., and Ip, C. (2001). Se-methylselenocysteine: a new compound for chemoprevention of breast cancer. Nutr. Cancer 40, 12-17.
40. Menter, D.G., Sabichi, A.L., and Lippman, S.M. (2000). Selenium effects on prostate cell growth. Cancer Epidemiol. Biomarkers Prev. 9, 1171-1182.
41. Nelson, P.S., Clegg, N., Arnold, H., Ferguson, C., Bonham, M., White, J., Hood, L., and Lin, B. (2002). The program of androgen-responsive genes in neoplastic prostate epithelium. Proc. Natl. Acad. Sci. USA 99, 11890-11895.
42. Nelson, W.G., De Marzo, A.M., Deweese, T.L., Lin, X., Brooks, J.D., Putzi, M.J., Nelson, C.P., Groopman, J.D., and Kensler, T.W. (2001). Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann. N.Y. Acad. Sci. 952, 135-144.
43. Nomura, A.M., Lee, J., Stemmermann, G.N., and Combs, G.F., Jr. (2000). Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 9, 883-887.
44. Rao, C.V., Wang, C.Q., Simi, B., Rodriguez, J.G., Cooma, I., El-Bayoumy, K., and Reddy, B.S. (2001). Chemoprevention of colon cancer by a glutathione conjugate of 1,4-phenylenebis(methylene)selenocyanate, a novel organoselenium compound with low toxicity. Cancer Res. 61, 3647-3652.
45. Reddy, B.S., Upadhyaya, P., Simi, B., and Rao, C.V. (1994). Evaluation of organoselenium compounds for potential chemopreventive properties in colon carcinogenesis. Anticancer Res. 14, 2509-2514.
46. Redman, C., Scott, J.A., Baines, A.T., Basye, J.L., Clark, L.C., Calley, C., Roe, D., Payne, C.M., and Nelson, M.A. (1998). Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett. 125, 103-110.
47. Sherlock, G., et al. (2001). The Stanford microarray database. Nucleic Acids Res. 29, 152-155.
48. Sherr, C.J., and Roberts, J.M. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512.
49. Sinha, R., Unni, E., Ganther, H.E., and Medina, D. (2001). Methylseleninic acid, a potent growth inhibitor of synchronized mouse mammary epithelial tumor cells in vitro. Biochem. Pharmacol. 61, 311-317.
50. Venkateswaran, V., Klotz, L.H., and Fleshner, N.E. (2002). Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res. 62, 2540-2545.
51. Wang, Z., Jiang, C., Ganther, H., and Lu, J. (2001). Antimitogenic and proapoptotic activities of methylseleninic acid in vascular endothelial cells and associated effects on PI3K-AKT, ERK, JNK and p38 MAPK signaling. Cancer Res. 61, 7171-7178.
52. Whitfield, M.L., et al. (2002). Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol. Biol. Cell 13, 1977-2000.
53. Willett, W.C., Polk, B.F., Morris, J.S., Stampfer, M.J., Pressel, S., Rosner, B., Taylor, J.O., Schneider, K., and Hames, C.G. (1983). Prediagnostic serum selenium and risk of cancer. Lancet 2, 130-134.
54. Williams, E.D., and Brooks, J.D. (2001). New molecular approaches for identifying novel targets, mechanisms, and biomarkers for prostate cancer chemopreventive agents. Urology 57, 100-102.
55. Xu, L.L., Su, Y.P., Labiche, R., Segawa, T., Shanmugam, N., McLeod, D.G., Moul, J.W., and Srivastava, S. (2001). Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. Int. J. Cancer 92, 322-328.
56. Yoshizawa, K., Willett, W.C., Morris, S.J., Stampfer, M.J., Spiegelman, D., Rimm, E.B., and Giovannucci, E. (1998). Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J. Natl. Cancer Inst. 90, 1219-1224.
57. Youn, B.W., Fiala, E.S., and Sohn, O.S. (2001). Mechanisms of organoselenium compounds in chemoprevention: effects on transcription factor-DNA binding. Nutr. Cancer 40, 28-33.
58. Zhang, Y., Ni, J., Messing, E.M., Chang, E., Yang, C.R., and Yeh, S. (2002). Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc. Natl. Acad. Sci. USA 99, 7408-7413.
59. Zhao, H., Hastie, T., Whitfield, M.L., Borresen-Dale, A.L., and Jeffrey, S.S. (2002). Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis. BMC Genomics 3, 31
60. Zhu, Z., Jiang, W., Ganther, H.E., and Thompson, H.J. (2002). Mechanisms of cell cycle arrest by methylseleninic acid. Cancer Res. 62, 156-164.